Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
Part of paid clinical trials in Philadelphia, Pennsylvania.
- Sponsor
- Karen Ballen, MD
- Study ID
- NCT05233618
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Myelofibrosis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Tagraxofusp — DRUGinpatient on days 1-3 of cycles 1-4 and days 1-2 of additional cycles
Study Details
In this study, tagraxofusp (Tag) is given to patients with CD 123+ myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) after allogeneic stem cell transplant (HCT) to help prevent relapse. Patients will receive up to about 9 cycles of treatment with Tag and have a bone marrow biopsy after cycle 4 and about 1 year after HCT.
Key Dates
- Start date
- Jul 13, 2022
- Status verified
- May 2025
- Primary completion
- Jul 1, 2026
- Completion
- Oct 1, 2026
Study Design
- Enrollment
- 44 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Tagraxofusp (escalating doses)IV tagraxofusp on days 1-3 of cycles 1-4 and days 1-2 of additional cycles for up to 9 cycles (some participants could receive more if considered in their best interest)
Primary Outcome Measure
Incidence and severity of grade ≥ 3 adverse events [ Time Frame: Through about 30 days following last infusion of tagraxofusp ]
Central Contacts
- Samantha Brooks4349823365
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | Samantha Matusiak Margaret Kasner, MD (PRINCIPAL_INVESTIGATOR) |
| University of Virginia | Charlottesville | Virginia | 22901 | Karen Ballen, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Philadelphia, PA
By condition
By specialty
Related Studies
- KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT ChildrenPHASE2 · Enrolling By Invitation · Michael Pulsipher · Los Angeles, California
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCTRecruiting · Children's Hospital of Philadelphia · Philadelphia, Pennsylvania
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)PHASE2 · Recruiting · Fred Hutchinson Cancer Center · Tampa, Florida